Moderna (MRNA)
(Real Time Quote from BATS)
$105.04 USD
-3.81 (-3.50%)
Updated Apr 25, 2024 12:13 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Average Brokerage Rating
Current ABR | 2.43 |
ABR (Last week) | 2.43 |
# of Recs in ABR | 21 |
Average Target Price | $131.75 |
LT Growth Rate | 17.60% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -3.59 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 9 | 9 | 9 | 8 | 9 |
Sell | 1 | 1 | 1 | 1 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.43 | 2.43 | 2.43 | 2.40 | 2.35 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/1/2024 | William Blair | Myles R Minter | Hold | Hold |
3/28/2024 | Guggenheim Securities | Evan Wang | Hold | Hold |
3/28/2024 | Needham & Company | Joseph R Stringer | Not Available | Hold |
2/23/2024 | Canaccord Genuity | William Maughan | Hold | Hold |
1/9/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
12/15/2023 | SVB Securities | Mani Foroohar | Strong Sell | Strong Sell |
12/1/2023 | Chardan Capital Markets | Yevgeniya Livshits | Hold | Hold |
11/2/2023 | Brookline Capital Markets | Leah R Cann | Strong Buy | Strong Buy |
9/13/2023 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.